Genzyme
Sanofi submits key MS pill for approval
June 12, 2012Research and Development, Sales and Marketing Bayer, EMA, FDA, Genzyme, Lemtrada, MS, Sanofi
Sanofi has submitted its multiple sclerosis pill Lemtrada for regulatory reviews in the US and Europe. Lemtrada (alemtuzumab), originally developed …
Genzyme boosts capacity following green light for Waterford plant
May 8, 2012Manufacturing and Production EMA, FDA, Genzyme, Sanofi, Waterford
Sanofi subsidiary Genzyme has doubled its capacity to fill-and-finish two of its drugs for rare disorders following approval of a …
Pfizer enters Gaucher disease market
May 3, 2012Sales and Marketing Cerezyme, Elelyso, Gaucher, Genzyme, Pfizer, Shire, Vpriv
Pfizer has gained FDA approval for its new Gaucher disease drug Elelyso. Elelyso (taliglucerase alfa) is an enzyme replacement therapy …
Shire’s Vpriv website in breach of ABPI Code
April 24, 2012Medical Communications, Sales and Marketing ABPI, Genzyme, PMCPA, Shire, Vpriv, code
Shire’s website for its Gaucher’s disease drug Vpriv has fallen foul of the ABPI’s Code of Conduct. The complaint was …
Genzyme starts shipping Fabrazyme from Framingham facility
March 6, 2012Manufacturing and Production Fabrazyme, Framingham, Genzyme
Sanofi subsidiary Genzyme has shipped the first supplies of Fabry disease treatment Fabrazyme produced at its new plant in Framingham, …
‘Rare Disease Day’ highlights need for research
February 29, 2012Research and Development, Sales and Marketing Genzyme, Rare Disease Day, Shire
Today has been designated as Rare Disease Day around the world, with researchers, regulators and the industry all raising awareness …
EMA accepts Genzyme MS drug for review
February 24, 2012Research and Development, Sales and Marketing EMA, Genzyme, Sanofi, teriflunomide
The European Medicines Agency has accepted Genzyme’s application for its multiple sclerosis pill teriflunomide. Genzyme, which is wholly owned by …
Genzyme to close UK site
February 24, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi, UK, job cuts
Genzyme will close its Cambridge R&D site by the end of the year, with a loss of around 60 jobs. …
Genzyme’s Framingham site cleared by FDA
January 24, 2012Manufacturing and Production FDA, Fabrazyme, Fabry, Genzyme
The FDA has cleared Genzyme to begin production of Fabrazyme at its new manufacturing site. The approval of the new …
Genzyme lifted by EU approval of Fabrazyme facility
January 20, 2012Manufacturing and Production Boston, EMA, Fabrazyme, Genzyme
Sanofi subsidiary Genzyme moved a crucial step closer to resolving its long-standing manufacturing problems after the European Medicines Agency gave …
Genzyme appoints new leaders for multiple sclerosis and rare disease businesses
November 14, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genzyme
Genzyme, a Sanofi company, has appointed William Sibold as head of multiple sclerosis and Rogério Vivaldi as head of rare …
David Meeker appointed as chief executive of Genzyme
October 25, 2011Research and Development, Sales and Marketing Genzyme, Sanofi
Sanofi has appointed David Meeker as chief executive of its new biotech acquisition Genzyme. He will report to Christopher Viehbacher, …
Genzyme completes expansion at Waterford plant
October 14, 2011Manufacturing and Production Genzyme, Sanofi
Sanofi’s Genzyme unit has officially opened a €150 million expansion at its ten-year-old biotechnology facility in Waterford, Ireland that will …
Genzyme confirms further Fabrazyme delay
September 13, 2011Manufacturing and Production Fabrazyme, Genzyme, pharma manufacturing news
Genzyme has been forced to delay shipments of its Fabry disease treatment Fabrazyme once again, blaming its “quality release process”. …
Sanofi banks on personalised medicine for growth
September 8, 2011Sales and Marketing Genzyme, Sanofi
Sanofi has nailed its colours to the mast of personalised medicine, banking on the purchase of US biotech company Genzyme, …
